Bastian Schilling Prof. Dr. med.Deputy Chair (Leitender Oberarzt), Department of Dermatology, University Hospital Würzburg, Germany
Dr. Bastian Schilling is Deputy Chair (Leitender Oberarzt) of the Department of Dermatology at the University Hospital of Würzburg in Germany, where he is also an associate professor in the department.
Dr. Schilling received his medical degree from the University of Duisburg-Essen and underwent residency training in dermatology at University Hospital Essen. He completed a postdoctoral fellowship in the Department of Pathology at the University of Pittsburgh Cancer Institute, in the US.
As a clinician treating patients with skin cancer and a scientist heading a lab concentrating on tumor immunology, Dr. Schilling focuses on skin cancer, particularly melanoma and translational melanoma research, tumor immunology and immunotherapy, and the immunological aspects of targeted therapies, among other areas of interest.
Dr. Schilling is on the advisory board or has received honoraria from Immunocore, Almirall, Pfizer, Sanofi, Novartis, Roche, BMS and MSD, research funding from Novartis and Pierre Fabre Pharmaceuticals, and travel support from Novartis, Roche, Bristol-Myers Squibb and Pierre Fabre Pharma.
Recent Contributions to PracticeUpdate:
- Decision-Making and HRQoL in Patients With Melanoma Considering Adjuvant Immunotherapy
- Clinical and Molecular Response to Tebentafusp in Patients With Previously Treated Metastatic Uveal Melanoma
- 2022 Top Story in Advanced Melanoma: Response-Driven Therapy After Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
- Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma
- Adjuvant Nivolumab Plus Ipilimumab vs Nivolumab Alone in Patients With Resected Stage IIIB–D/IV Melanoma
- Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
- ESMO 2022: Recommendations From Dr. Bastian Schilling for Advanced Melanoma
- Baseline and Post-Treatment Biomarkers of Resistance to Anti–PD-1 Therapy in Acral and Mucosal Melanoma
- Efficacy of Anti–PD-1 Therapy and/or Ipilimumab in Acral Melanoma
- Dabrafenib Plus Trametinib in Elderly Patients With BRAF V600–Mutant Advanced Melanoma